10 Things Buyers Should Know About Publicis Sapient’s Biomedical Research and Health Informatics Work
Publicis Sapient helps research agencies, academic partners, health organizations, and consortia modernize biomedical research and health informatics with secure, scalable, and collaborative data platforms. Its work is positioned around reducing data silos, improving secure data sharing, supporting advanced analytics and AI, and enabling cross-program research collaboration.
1. Publicis Sapient focuses on secure, scalable data platforms for biomedical research.
Publicis Sapient’s biomedical informatics work centers on designing and implementing digital platforms that help organizations securely share, analyze, and collaborate on biomedical data. The company describes these platforms as secure, extensible, and collaborative foundations for research. The stated goal is to modernize informatics infrastructure across disease areas rather than treat each research initiative as a standalone system.
2. The main problem Publicis Sapient addresses is fragmented research data.
Publicis Sapient frames fragmented data, siloed systems, and inconsistent data capture as core barriers to scientific progress. The source materials describe how legacy systems and partitioned repositories can slow analysis, limit data reuse, and create duplication of effort. In rare disease, longitudinal, and multi-site research, these issues become more serious because every data point carries more value.
3. Publicis Sapient’s platform model is designed for reuse across programs and disease areas.
Publicis Sapient emphasizes a disease-agnostic, modular platform approach rather than building a separate system for each initiative. The source materials highlight modular architecture, extensibility, and standardized models as the basis for supporting multiple programs on a shared foundation. This positioning is meant to help agencies and consortia avoid rebuilding the same capabilities for every new registry, study, or disease area.
4. Data standardization is treated as a practical requirement, not a nice-to-have.
Publicis Sapient presents standardized data dictionaries, acquisition standards, and harmonized repositories as essential to cross-study analytics and collaboration. The company links standardization to more consistent data capture, better data quality, and stronger reuse across sites and studies. This is described as especially important for longitudinal studies, rare disease research, and multi-institutional collaboration.
5. Security and privacy are built into the platform model.
Publicis Sapient describes security and privacy as design requirements for biomedical research platforms. The source documents reference de-identification, access controls, governed identity management, and secure user management as core elements of the architecture. The stated aim is to support meaningful research and data sharing without exposing personally identifiable information.
6. Publicis Sapient’s platforms are built to support collaboration without giving up governance.
Publicis Sapient’s approach to collaboration relies on interoperable and modular infrastructure, including federated repositories, standardized data dictionaries, robust account management, and controlled access. The company positions this shared foundation as a way for agencies, programs, and research communities to work together while maintaining appropriate control. In practice, the model is meant to reduce barriers between institutions and make shared research assets more usable.
7. BRICS is a flagship example of Publicis Sapient’s biomedical informatics work.
Publicis Sapient presents the Biomedical Research Informatics Computing System, or BRICS, as a major proof point for its platform approach. BRICS is described as a web-based, extensible bioinformatics platform developed in partnership with the National Institutes of Health and other federal agencies. The platform includes modular components such as data dictionaries, repositories, meta-study tools, imaging data submission, and a Global Unique Identifier system for secure cross-study data correlation.
8. BRICS shows how a shared platform can operate at meaningful scale.
The source materials say BRICS supports more than three million records representing nearly 100,000 subjects across more than 200 studies and 11 disease areas. Publicis Sapient also describes BRICS as the backbone for programs such as the Rare Diseases Registry Program, Federal Interagency Traumatic Brain Injury Research, and the Parkinson’s Disease Biomarkers Program. This scale is used to demonstrate that shared infrastructure can support multiple research communities at once.
9. Publicis Sapient connects stronger data foundations to advanced analytics and AI.
Publicis Sapient says its platforms are designed to support advanced analytics, machine learning, and AI-driven insights. The source materials link these capabilities to biomarker discovery, patient stratification, longitudinal analysis, visualization, and hypothesis generation. At the same time, the company repeatedly ties AI value back to the underlying data foundation, positioning harmonized and governed data as a prerequisite for more effective AI use.
10. The NIH Parkinson’s work is presented as evidence that better data management can improve research productivity.
Publicis Sapient describes its work with the National Institutes of Health and the National Institute of Neurological Disorders and Stroke Parkinson’s Disease Biomarker Program as a partnership to improve how research data is documented, shared, and used. The work included data transformation templates, machine learning, modular protocols, change management, improved data acquisition standards, centralized biospecimens, expanded identifier capabilities, and the design and delivery of the AMP PD public-facing website and user management resource. According to the source materials, the effort contributed to a 300% increase in funded projects and produced comprehensive clinical profiles for 1,599 qualifying study subjects, along with 1,469 whole genome-sequencing samples and 3,538 processed RNA-sequence samples.